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A B S T R A C T
Aim. – To describe in type 2 diabetes the 24-hour distribution of hypoglycaemia and compare the
frequency of nocturnal events based on a predefined nocturnal window or an expanded interval, using
illustrative data for two insulin glargine formulations.
Methods. – Temporal distribution of hypoglycaemic events was assessed descriptively and by profile
using participant-level data from three randomized trials comparing insulin glargine 300 U/mL (Gla-
300) and 100 U/mL (Gla-100). Risk of hypoglycaemia and annualized event rates were compared for the
predefined nocturnal interval (00:00 to 05:59 h) and an expanded window (22:00 h to the pre-breakfast
glucose measurement).
Results. – Confirmed ( 3.9 mmol/L [ 70 mg/dL]) or severe hypoglycaemic events were reported most
frequently between 06:00 and 10:00 h with both insulins. Nearly threefold more events were identified
using the expanded nocturnal interval. Risk of  1 nocturnal event was 25% lower with Gla-300 than Gla-
100 with the predefined, and 16% lower with the expanded interval; annualized event rates were 31%
and 24% lower with the predefined and expanded window, respectively. The between-insulin difference
in number of nocturnal events depended markedly on the chosen nocturnal interval (556 vs. 1145 fewer
events with Gla-300 using the predefined vs. expanded interval).
Conclusions. – The predefined 00:00–05:59 h nocturnal interval excluded many hypoglycaemic events
occurring during the actual overnight interval. While Gla-300 reduced hypoglycaemic events versus Gla-
100 (regardless of the interval considered), the results obtained using the expanded window better
reflect the clinical experience of people treated with basal insulin.
C 2017 Published by Elsevier Masson SAS.
Available online at
ScienceDirect
www.sciencedirect.comIntroduction
Hypoglycaemia is a leading barrier to attaining glycaemic goals
with insulin therapy [1]. Nocturnal hypoglycaemia may be
particularly alarming to individuals with diabetes and providers,
and disruptive to medical management [2–4]. Recent clinical trials
investigating the use of new long-acting insulin preparations in
type 2 diabetes (T2DM) have examined the frequency of nocturnal* Corresponding author. Oregon Health & Science University L-345, 3181 SW Sam
Jackson Park Road, Portland, OR 97239–3098, USA.
E-mail address: riddlem@ohsu.edu (M.C. Riddle).
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1262-3636/C 2017 Published by Elsevier Masson SAS.hypoglycaemia to determine whether this unwanted effect is
reduced with the newer products. Nocturnal hypoglycaemia has
usually been defined as occurring between 00:00 and 05:59 h, to
limit the inclusion of hypoglycaemia potentially related to
mealtime insulin taken after wakening. However, this 6-hour
window may not include all events occurring during the period
between waking and breakfast, during which fasting continues and
glucose is still regulated by basal insulin; it also does not include
the period between an evening injection of basal insulin and
midnight. Thus, many events of hypoglycaemia related to basal
insulin during the night will be ignored when assessing differences
between insulins.poglycaemia during basal insulin therapy: Temporal distribution
cturnal events. Diabetes Metab (2017), https://doi.org/10.1016/
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hypoglycaemic events using participant-level data available from
three trials of insulin glargine (EDITION 1–3) in T2DM [5–7]. In
addition to the number and timing of hypoglycaemic events, the
times of evening insulin injections and of pre-breakfast self-
measured glucose tests were routinely collected in the EDITION
trials, and assessments were made of the incidence and rate of
hypoglycaemia meeting the primary hypoglycaemia definition and
an alternative definition of < 3.0 mmol/L (< 54 mg/dL). Using this
information, we examined the effect of including events occurring
in a wider nocturnal window, defined as the interval between
22:00 h and the pre-breakfast glucose test for each participant, as
compared with the 00:00–05.59 h interval that was predefined as
‘‘nocturnal’’ in these trials. Because the trials were randomized
comparisons of treatment with insulin glargine 300 U/mL (Gla-
300) or insulin glargine 100 U/mL (Gla-100), our analysis allowed
evaluation of the effect of the nocturnal interval chosen on the
observed differences between these insulins.
Materials and methods
Data sources and participants
EDITION 1, 2, and 3 were multicentre, randomized, open-label,
two-arm, parallel-group, phase 3a trials (NCT01499082,
NCT01499095, NCT01676220) of similar designs that have been
described previously [5–7]. In EDITION 1, participants had
previously followed a regimen of basal insulin therapy with either
Gla-100 or neutral protamine Hagedorn (NPH) insulin ( 42 U/day),
together with mealtime insulin therapy, with or without metformin,
for at least 1 year. In EDITION 2, participants had used basal insulin
(Gla-100 or NPH insulin;  42 U/day) for more than 6 months,
combined with oral anti-hyperglycaemic drugs (OADs) within the
previous 4 weeks. Participants in EDITION 3 were insulin-naı¨ve and
were required to have used OADs for at least 6 months before
screening. In addition, sulfonylureas were to be discontinued in
EDITION 2 (2 months prior to screening) and in EDITION 3 (at
baseline). All participants provided written, informed consent. All
three protocols were approved by the appropriate ethics commit-
tees and the trials were conducted according to Good Clinical
Practice and the principles of the Declaration of Helsinki.
After a 2-week screening phase, each trial included a 6-month
main on-treatment period; data from this are included in the
present analysis. No participants were < 18 years of age or had
glycated haemoglobin (HbA1c) < 7.0% (53 mmol/moL), or > 10.0%
(86 mmol/moL) for EDITION 1 and 2, and > 11.0% (97 mmol/moL)
for EDITION 3. Further details of inclusion and exclusion criteria
have been reported previously [5–7] and are summarized in Table
S1 (see supplementary materials associated with this article online).
Therapy
Participants were randomized (1:1) to receive once-daily subcu-
taneous injections of either Gla-300 or Gla-100 (both Sanofi, Paris
France) as described previously (6–8). The basal insulin injection was
administered in the evening from before dinner to bedtime, and at the
same time for everyone during the 6 months of randomized therapy.
Basal insulin injection time was recorded by all participants. Basal
insulin dosage was adjusted seeking a fasting, pre-breakfast, self-
monitored plasma glucose (SMPG) target of 4.4–5.6 mmol/L (80–
100 mg/dL), using specific titration algorithms [5–7].
Outcomes
The pre-specified hypoglycaemia endpoints were the same for
each trial [5–7]. Briefly, all hypoglycaemic events were categorized
according to the American Diabetes Association definitions [8]:Please cite this article in press as: Riddle MC, et al. Assessment of hy
and risk of events using a predefined or an expanded definition of n
j.diabet.2017.12.001 severe hypoglycaemia (an event requiring the assistance of
another person to actively administer carbohydrate, glucagon or
other resuscitative actions);
 documented symptomatic hypoglycaemia (an event during
which typical symptoms of hypoglycaemia are confirmed by an
SMPG measurement of  3.9 mmol/L [ 70 mg/dL]);
 and asymptomatic hypoglycaemia identified by an SMPG
measurement of  3.9 mmol/L ( 70 mg/dL).
The main analysis of hypoglycaemic events used the combina-
tion of the confirmed (with or without symptoms) and severe
categories. Hypoglycaemic events with a plasma glucose mea-
surement of < 3.0 mmol/L (< 54 mg/dL) were also analysed and
reported.
Data analysis and statistics
All analyses included all participants randomized and exposed
to  1 dose of trial drug. In each trial’s protocol, hypoglycaemic
events recorded between 00:00 h and 05:59 h were defined as
nocturnal events (‘‘predefined definition’’). In the current post hoc
analysis, an expanded window of nocturnal hypoglycaemia was
defined using a fixed start time (22:00 h), and a pre-breakfast time
defined for everyone by the median value of all pre-breakfast times
collected on pre-breakfast, 4- or 8-point SMPG (‘‘expanded
definition’’).
Hypoglycaemic events were reported as the number and
percentages of participants having  1 hypoglycaemic event over
6 months, the total number of events, and the annualized rate of
events (events per participant-year). Relative risk for participants
to have  1 hypoglycaemic event was estimated using the
Cochran–Mantel–Haenszel method. The rates of hypoglycaemia
were analysed using an over-dispersed Poisson regression model
with treatment and randomization strata of screening HbA1c
(< 8.0 and  8.0% [< 64 and  64 mmol/moL]) and trial as fixed
effects, and logarithm of the duration of the treatment period as
offset.
Although the EDITION 1, 2, and 3 studies were conducted in
different populations, the consistent study designs and endpoints
allowed a pooled analysis to be performed. The main analysis used
pooled patient-level data from the EDITION 1, 2, and 3 studies
(EDITION 1 + 2 + 3). In addition, to examine the data without the
potentially confounding effect of the mealtime insulin used in
EDITION 1, pooled patient-level data from the EDITION 2 and
3 studies (EDITION 2 + 3) were included in a secondary analysis.
Data from each individual trial are also given as supportive
information.
Results
Study population
Taken together, the EDITION 1, 2, and 3 trials randomized
2496 participants of whom 2488 were treated with study insulin
and are included here. Baseline characteristics of participants in
the pooled populations are provided in Table 1; those for
participants in each trial have been previously reported [5–7]
and are provided in Table S2 (see supplementary materials
associated with this article online). Important differences
between the trial populations are evident. Notably, participants
in EDITION 1 (who were all users of basal and mealtime insulin)
were approximately 2 years older on average and had 3–6 years
longer duration of diabetes than those in EDITION 2 and
3. Participants in EDITION 1 had also used insulin for longer
than those in EDITION 2.poglycaemia during basal insulin therapy: Temporal distribution
octurnal events. Diabetes Metab (2017), https://doi.org/10.1016/
Table 1
Baseline characteristics based on pooled data from the EDITION 1 + 2 + 3 and EDITION 2 + 3 trials in type 2 diabetes (randomized populations).
EDITION 1 + 2 + 3 EDITION 2 + 3
Gla-300
(n = 1247)
Gla-100
(n = 1249)
Gla-300
(n = 843)
Gla-100
(n = 846)
Age, years 58.7  9.3 58.5  9.5 58.0  9.5 57.9  9.8
Gender (male), n (%) 657 (53) 649 (52) 440 (52) 439 (52)
Body weight, kg 99.9  22.8 99.9  21.7 96.8  22.9 96.7  21.8
BMI, kg/m2 34.7  6.9 34.8  6.4 33.8  6.8 34.0  6.4
Duration of type 2 diabetes, years 12.7  7.2 12.6  7.5 11.4  6.9 11.0  6.8
Duration of basal insulin treatmenta, years 5.2  4.5 5.2  4.3 3.8  3.7 3.8  3.3
Prior use of insulin glarginea,b, n (%) 677 (84) 706 (87) 304 (75) 337 (83)
Prior use of OADsa, n (%)
Biguanides 1010 (81) 1022 (82) 784 (93) 787 (93)
Sulfonylureasc 276 (22) 269 (22) 275 (33) 269 (32)
DPP-4 inhibitors 123 (10) 149 (12) 123 (15) 151 (18)
HbA1c, % [mmol/moL] 8.31  0.92
[67.3  10.1]
8.32  0.91
[67.4  9.9]
8.39  0.97
[68.2  10.6]
8.40  0.95
[68.3  10.4]
DPP: dipeptidyl peptidase; OAD: oral antihyperglycemic agent; SD: standard deviation. Values are mean  SD unless otherwise stated.
a Data from EDITION 3 were not included as this trial was conducted in insulin-naı¨ve participants.
b Taken within 3 months prior to randomization.
c Sulfonylureas were to be discontinued in EDITION 2 (2 months prior to screening) and in EDITION 3 (at baseline).
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glucose tests
The temporal distributions of basal insulin injections and of
SMPG tests before breakfast are shown separately for each trial in
Fig. S1 (see supplementary materials associated with this article
online), and the pooled data are provided in Table S3 (see
supplementary materials associated with this article online).
Despite the differences in clinical characteristics between the trial
populations, the distributions of times of basal insulin injections
and pre-breakfast SMPG testing were similar. For all three trials
combined, the median time of the glucose test was 07:30 h and
that of insulin injection was 21:30 h. However, there was
considerable variation, with some individuals doing the glucose
test before 05:00 h or after 10:00 h and some taking the injection
before 18:00 h or after 01:00 h.
Pattern of hypoglycaemic events by time of day
The 24-h temporal patterns of hypoglycaemic events that were
confirmed or severe are shown in Fig. 1A–1D. By inspection, both
the percentage of participants with  1 events and the event rates
were lowest in the early morning hours and highest between 06:00
and 10:00 h. The patterns for the individual studies are similar
(Fig. 1B, 1D), except for the period after 10:00 h in EDITION 1, in
which mealtime insulin was given and more hypoglycaemic events
were reported than in EDITION 2 and 3.
Number of hypoglycaemic events by nocturnal interval
The numbers of events identified between 00:00 and 05:59 h
and between 22:00 h and the pre-breakfast SMPG are shown in
Table 2. With data pooled from all three trials, 3026 events were
reported in the predefined interval, and 8315 in the expanded
interval (Table 2). Nocturnal events constituted 15.7% of the daily
total using the predefined 00:00–05:59 h interval, and 43.1% of
events using the expanded interval. The increase in the percentage
of daily events classified as nocturnal with the expanded interval
was especially prominent in EDITION 2 and 3, in which mealtime
insulin was not used. In those two trials, the percentage of events
identified as nocturnal increased from 17.5% to 50.5% with the
expanded definition.Please cite this article in press as: Riddle MC, et al. Assessment of hy
and risk of events using a predefined or an expanded definition of no
j.diabet.2017.12.001Risk of experiencing various categories of hypoglycaemia with Gla-300
and Gla-100, by treatment and nocturnal interval and glucose
confirmation level
In the analysis of data pooled from all three trials, the
percentage of participants experiencing  1 nocturnal event was
lower with Gla-300 than Gla-100 using both the 00:00–05:59 h
interval (relative risk [RR] 0.75, 95% confidence interval [CI] 0.68 to
0.83) and the 22:00 h to pre-breakfast SMPG window (RR 0.84, 95%
CI 0.78 to 0.89) (Fig. 2A). A consistent pattern of lower risk for Gla-
300 compared with Gla-100 was also observed for both nocturnal
intervals when < 3.0 mmol/L (< 54 mg/dL) was used as the
defining glycaemic threshold or with other categories of hypo-
glycaemia (Fig. 3A). While the differences between the upper and
lower confidence limits narrowed with the higher numbers in the
expanded interval versus the predefined nocturnal window, the
shifts in the central estimates did not fall outside the paired
confidence interval and, in general, were small (Fig. 2A, 3A).
From the analysis of EDITION 2 + 3 together, which excludes the
potential confounding effect of mealtime insulin, there was also a
lower risk of hypoglycaemia for Gla-300 compared with Gla-100
for confirmed ( 3.9 mmol/L [ 70 mg/dL]) or severe hypoglycae-
mic events for both nocturnal intervals (Fig. 2A). Similar patterns
were observed in each of these trials separately and for other
categories of hypoglycaemia (Fig. 2A, Table S4; see supplementary
materials associated with this article online).
Rate of hypoglycaemic events by treatment, nocturnal window, and
glucose confirmation level
Event rates (event per participant-year) were lower with Gla-300
than Gla-100 in analysis of data from all three trials using both the
predefined interval (rate ratio [RR] 0.69, 95% CI 0.57 to 0.84) and the
expanded window (RR 0.76, 95% CI 0.66 to 0.87) (Fig. 2B). Similar
patterns were seen for each trial separately, for data from EDITION
2 + 3 only, for the other glycaemic threshold (< 3.0 mmol/L
[< 54 mg/dL]), and for other definitions of hypoglycaemia (Fig. 3B).
The total numbers of events reported during therapy with each
glargine formulation in each of the nocturnal intervals are shown
in Table 2. In all three trials together, 1791 confirmed or severe
events occurred with Gla-100 in the predefined interval and
1235 with Gla-300, a difference of 556 events. In the expanded
nocturnal interval, there were 4730 events with Gla-100 and
3585 with Gla-300, a difference of 1145 events.poglycaemia during basal insulin therapy: Temporal distribution
cturnal events. Diabetes Metab (2017), https://doi.org/10.1016/
Fig. 1. Percentage of participants with  1 confirmed ( 3.9 mmol/L [ 70 mg/dL]) or severe hypoglycaemic events (A, B), and annualized rate of confirmed ( 3.9 mmol/L
[ 70 mg/dL]) or severe hypoglycaemia events (C, D) by time during the 6-month treatment period in (A, C) EDITION 1 + 2 + 3 safety population and (B, D) individual EDITION
1, 2, and 3 trial safety populations.
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These post hoc analyses of data from EDITION 1, 2, and
3 provide new information about the temporal distribution of
hypoglycaemic events during daily life in a broad range of people
with T2DM on insulin (basal only, and basal-bolus). The most
important observation was that events were reported most
frequently between 06:00 and 10:00 h, and this was observed
with both basal insulin preparations. The fasting glucose
measurement, which was to be taken immediately before
breakfast, was typically measured close to 07:30 h. Consequently,
many nocturnal events were excluded from computation of risk for
the overnight fasting period when the predefined nocturnalPlease cite this article in press as: Riddle MC, et al. Assessment of hy
and risk of events using a predefined or an expanded definition of n
j.diabet.2017.12.001window (00:00–05:59 h) was used. The difference in numbers
of events identified in the predefined versus the expanded
nocturnal window is important. Almost three times as many
events (8315 vs. 3026) were reported as nocturnal, and most likely
related to basal insulin treatment, with the expanded definition. In
those not using mealtime insulin (only basal insulin), the
percentage of all events in a 24-hour observation period defined
as ‘nocturnal’ was about 18% with the predefined interval versus
51% with the expanded definition. This finding suggests specificity
of the expanded definition in detecting hypoglycaemia induced by
basal insulin even in participants on basal-bolus insulin. Thus, the
expanded definition of nocturnal events may provide a more
complete description of the risk of nocturnal hypoglycaemiapoglycaemia during basal insulin therapy: Temporal distribution
octurnal events. Diabetes Metab (2017), https://doi.org/10.1016/
Table 2
Number of confirmed ( 3.9 mmol/L [ 70 mg/dL]) or severe hypoglycaemic events during the 6-month treatment period by nocturnal window in individuals with type
2 diabetes (safety populations).
Number of events
Any time (24 h) Nocturnal
(00:00–05:59 h)
Daytime
(06:00–23:59 h)
24-h events defined
as nocturnal (%)
Nocturnal
(22:00 h to
pre-breakfast
SMPG)
Daytime (pre-breakfast
SMPG–21:59 h)
24-h events
defined as nocturnal (%)
EDITION 1 + 2 + 3
Gla-300 8935 1235 7700 13.8 3585 5350 40.1
Gla-100 10373 1791 8582 17.3 4730 5643 45.6
Total 19308 3026 16282 15.7 8315 10993 43.1
EDITION 2 + 3
Gla-300 3969 625 3344 15.7 1953 2016 49.2
Gla-100 5197 978 4219 18.8 2672 2525 51.4
Total 9166 1603 7563 17.5 4625 4541 50.5
EDITION 1
Gla-300 4966 610 4356 12.3 1632 3334 32.9
Gla-100 5176 813 4363 15.7 2058 3118 39.8
Total 10142 1423 8719 14.0 3690 6452 36.4
EDITION 2
Gla-300 2680 362 2318 13.5 1288 1392 48.1
Gla-100 3156 713 2803 20.3 1913 1603 54.4
Total 6196 1075 5121 17.3 3201 2995 51.7
EDITION 3
Gla-300 1289 263 1026 20.4 665 624 51.6
Gla-100 1681 265 1416 15.8 759 922 45.2
Total 2970 528 2442 17.8 1424 1546 47.9
SMPG: self-monitored plasma glucose.
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more statistical power.
The high incidences of hypoglycaemia and event rates reported
in EDITION 1, 2, and 3 in the intervals 06:00–08:00 h and 08:00–
10:00 h may have several explanations. Firstly, SMPG measure-
ments are more likely to be made at these times than during the
midnight time and early-morning hours, and the definition of
hypoglycaemia utilized required confirmation for both symptom-
atic and asymptomatic events by such measurements. Secondly,
sleep is known to suppress awareness of hypoglycaemia [9],
including adrenergic symptoms, so it is more likely to be detected
after normal waking. In addition, long-acting basal insulin
preparations may increase the risk of hypoglycaemia during
prolonged fasting, and it seems likely that people who waken later
and delay breakfast longer may risk hypoglycaemia more than
those who arise earlier and have shorter duration of overnight
fasting. Regardless of the explanation, the pattern of nocturnal
hypoglycaemia with long-acting insulin glargine, both Gla-100
[10] and Gla-300 (present study) is different from that reported
with NPH insulin [10], for which the risk of hypoglycaemia
increases sharply in the earlier hours of the night, presumably
related to differences in pharmacokinetics [11].
The increased power of the broader definition of nocturnal
hypoglycaemia can be seen in Fig. 2, where the confidence
intervals are much narrower than for the original predefined
definition. However, as the original confidence intervals generally
do not cross 1.00, the qualitative conclusion of a hypoglycaemia
advantage for Gla-300 over Gla-100 from prior analyses is not
changed [5–7]. While it is evident from Fig. 1 that the direction of
advantage for the intervals 06:00–08:00 h and 08:00–10:00 h is
the same as the two prior intervals after 02:00 h, there is a trend in
the data presented in Fig. 2 for the relative risk and rate ratios to be
closer to 1.00 (although still mostly statistically significant) using
the expanded definition that extends past 06:00 h. This observa-
tion might suggest a downside to the expanded definition, namely
that more events after 06:00 h were not amenable to an
improvement with a better basal insulin, but rather reflect the
lack of minute-to-minute control of insulin delivery when using
subcutaneous injections.Please cite this article in press as: Riddle MC, et al. Assessment of hy
and risk of events using a predefined or an expanded definition of no
j.diabet.2017.12.001It has recently been suggested that the glucose confirmation
level for hypoglycaemia reported in clinical trials should be
lowered to < 3.0 mmol/L (< 54 mg/dL) [12,13]. Like nearly all
phase 3 trials of the newer longer-acting insulins, the EDITION 1–3
trials were not specifically powered to verify differences in the risk
of hypoglycaemia, and suffer further in this respect with the lower
numbers of hypoglycaemic events confirmed below 3.0 mmol/L.
Allowing for that context, analyses performed using that lower
glycaemic cut-off do not lead to different conclusions regarding
risks between the two definitions of nocturnal hypoglycaemia than
were found using the more traditional threshold (Table S4; see
supplementary materials associated with this article online).
The findings of these analyses build upon and extend those of
two other studies [10,14]. The original Treat-to-Target Trial
defined nocturnal hypoglycaemia as occurring after the bedtime
injection and before the routine pre-breakfast glucose test,
breakfast itself, or administration of any OAD in the morning.
Both the percentages of participants affected and event rates
peaked sharply between 02:00 and 07:00 h, with significant
between-treatment differences (Gla-100 versus NPH insulin)
favouring the basal analog throughout that interval. At 10:00 h
hypoglycaemia was slightly more common with Gla-100 than
NPH. In the EDITION trials, the risk of hypoglycaemia appeared to
extend later into the morning than in this earlier trial, consistent
with the longer durations of action of Gla-100 and Gla-300
compared with NPH, thereby exposing the limitation of the
predefined 00:00–05:59 h interval in recognizing events after
06:00 h but prior to breakfast.
More recently, an analysis of experience with Gla-100 versus
insulin degludec was reported using the conventional nocturnal
interval (00:00–05:59 h) and two expanded intervals, 21:59–
05:59 h and 00:01–07:59 h [14]. Data were pooled from three
trials enrolling insulin-naı¨ve participants and one enrolling
participants on mealtime and basal insulin therapy. The results
of most analyses were consistent across all three definitions of the
nocturnal interval, showing significantly less hypoglycaemia with
the new analog. This result confirms our finding that the definition
used, in the context of current clinical trial design, does not alter
the conclusion that hypoglycaemia during overnight fasting ispoglycaemia during basal insulin therapy: Temporal distribution
cturnal events. Diabetes Metab (2017), https://doi.org/10.1016/
Fig. 2. Hypoglycaemia during the 6-month treatment period by nocturnal window (EDITION 1 + 2 + 3; safety population). A. Percentage of participants with  1 confirmed
( 3.9 mmol/L [ 70 mg/dL]) or severe hypoglycaemic event. B. Rate of confirmed ( 3.9 mmol/L [ 70 mg/dL]) or severe hypoglycaemic events. CI, confidence interval;
SMPG, self-monitored plasma glucose.
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additionally define the degree to which the 00:00–05:59 h
nocturnal window misses clinically important hypoglycaemic
events.
Despite highlighting important limitations of using the 00:00–
05:59 h window in assessing the risk of nocturnal hypoglycaemia
during treatment with insulin, our analyses do not overcome other
difficulties in the interpretation of data from clinical trials. These
include the potential for under-reporting of nocturnal events
during sleep that do not awaken the individual, and increasedPlease cite this article in press as: Riddle MC, et al. Assessment of hy
and risk of events using a predefined or an expanded definition of n
j.diabet.2017.12.001ascertainment of asymptomatic events before breakfast when pre-
breakfast glucose tests are done frequently. Use of continuous
glucose monitoring devices in future studies would allow
collection of data that are less confounded by such factors
[15]. Another problem, both for clinical practice and clinical
research, is that posed by people with diabetes who have widely
varying daily schedules for sleep and meals, or reversed day–night
schedules compared with the general population. The few but
widely displaced outliers in their time of basal insulin injection or
pre-breakfast glucose testing in this dataset illustrate this concern.poglycaemia during basal insulin therapy: Temporal distribution
octurnal events. Diabetes Metab (2017), https://doi.org/10.1016/
Fig. 3. Hypoglycaemia during the 6-month treatment period by nocturnal/fasting window (EDITION 1 + 2 + 3). A. Number (%) of participants and relative risk of  1 event. B.
Annualized number of events (events per participant-year) and rate ratio (safety population). CI: confidence interval; SMPG: self-monitored plasma glucose.
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concept of nocturnal as distinguished from daytime hypoglycae-
mia may be less useful, and assessment of the full 24-hour risk of
hypoglycaemia more relevant.
In summary, these analyses demonstrate that, in different
populations of people with T2DM treated with regimens including
basal insulin, many hypoglycaemic events occurring during the
overnight fasting period were not identified by use of the
predefined 00:00–05:59 h definition of nocturnal hypoglycaemia.
Expanding this definition to include the time between late evening
and breakfast time (i.e., a fasting temporal interval during which
people with T2DM treated with basal insulin may be at risk of
hypoglycaemia regardless of it being night or day) increased the
number of events identified by up to threefold and may provide a
more clinically relevant assessment of risk during titration of basal
insulin. However, the relative risk and rate ratio for nocturnal
hypoglycaemic events with Gla-300 versus Gla-100 were con-Please cite this article in press as: Riddle MC, et al. Assessment of hy
and risk of events using a predefined or an expanded definition of no
j.diabet.2017.12.001firmed to be significantly lower with Gla-300 using both
definitions of the nocturnal window.
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